CClinicalTrials.gg
CompletedNCT05351957Updated Apr 28, 2022

Dry Needling for Treating Spasticity in Multiple Sclerosis

An interventional study of Dry needling in Multiple Sclerosis, sponsored by Hospital Universitario de Canarias. Completed at 1 site in Spain. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-28.

Sponsored by Hospital Universitario de Canarias · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 2 months after the study started (first participant enrolled Feb 2018, registered Apr 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The aim of the study is to evaluate the efficacy of dry needling (DN) in the treatment of spasticity in patients with multiple sclerosis (MS). [Participants and Methods] participants with MS, with no evidence of a relapse in the last four weeks and with an EDSS (Expanded Disability Sta- tus Scale) greater than 2.5 points (related with pyramidal score) were recruited. DN was performed in lower limbs for 12 consecutive sessions and evaluated with: EDSS (Pyramidal item), Time up and go (TUG), 25 foot, 9hold peg test (9HPT) and the improvement or not in the quality of life (MSQol54) was verified before and after treatment. A follow up visit was carried out to assess improvement.

02

Conditions studied

  • Multiple Sclerosis

Keywords

  • Dry needling, multiple sclerosis, physiotherapy
03

In context

Multiple Sclerosis

3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.

This study's enrollment of 10 is below the median of 50 across 2,342 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Hospital Universitario de Canarias is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Being a patient diagnosed with multiple sclerosis.
  • Being over 18 years of age and less than or equal to 60 years of age.
  • Having a score equal to or greater than 2 in the EDSS.
  • They need to have a measurement in the following functional systems: P (pyramidal) >2, CT (brainstem), gait >2 and sphincter >2.
  • They need to present hypertonia or contractures of the muscles selected for the dry needling, the pain expressed by the patients must be a consequence of spastic processes, have hourly availability to receive therapies and not have needle phobias.

Exclusion criteria

Exclusion Criteria:

  • Having a disease associated with multiple sclerosis that is incompatible with dry needling.
  • Being in relapse, or having suffered it in the thirty days prior to starting the treatment. program or taking medications that are contraindicated with the technique applied in the study, (oral anticoagulants.)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    dry needling

    This study has only 1 arm and the control group is their baseline data

    Procedure: Dry needling

Interventions

  • ProcedureDry needling

    Only dry needling of the lower limbs will performed in all patients with acupunture needling

06

What researchers measure

Primary outcomes

  1. Change in 9HOLD PEG TEST score

    This consists of placing the pegs in the corresponding holes of the 9 holes in the table in the shortest possible time (seconds)

    Time frame: inmediatly before and inmediatly after intervention

  2. Change in 25 foot walk score

    patients must walk a distance of 7.25 meters at the fastest and safest speed for them (seconds)

    Time frame: inmediatly before and inmediatly after intervention

  3. Change in Time up and go test score

    The participants sit in a chair with their backs supported by the back of the chair and their arms resting on the armrests. The participants are asked to get up from the chair and walk a distance of 3 meters, then the patients turn on themselves (360°), walk back to the chair and sit down again (seconds)

    Time frame: inmediatly before and inmediatly after intervention

  4. Change in Expanded Disability Status Scale (EDSS) score

    Each item is valued individually and a score is given, which will then outline the patient's total EDSS ranging from 0 to 10, for use in the exploration sessions. All scans were carried out by a blind explorer.

    Time frame: inmediatly before and inmediatly after intervention

  5. Change in Multiple sclerosis Quality of life-54 (MSQol54) score

    questionnaire of 54 items measuring the quality of life of the patient. It can be self-administered or hetero-administered and both physical and mental aspects are measured. Within these there are subscales: among them quality of life in general. Two summary scores, physical health and mental health, can be derived from a weighted combination of scale scores. They range from 0 to 100, where 100 is the highest quality of life (both for physical and mental health)

    Time frame: inmediatly before and inmediatly after intervention

07

Study locations

1 site
  • Hospital Universitario de Canarias
    La Laguna, Santa Cruz De Tenerife 38320, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05351957
Lead sponsor
Hospital Universitario de Canarias
Responsible party
Alberto Javier Ormazábal (Physiotherapist, Hospital Universitario de Canarias) — Principal investigator
First posted
Apr 28, 2022
Start date
Feb 18, 2018
Primary completion
Apr 20, 2020
Completion
Sep 22, 2020
Last update
Apr 28, 2022

Study contacts

MONSERRAT GONZÁLEZ-PLATAS
study director · Hospital Universitario de Canarias

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion